Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report

Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report

Abstract Background NRG1 fusions are rare oncogenic drivers in solid tumors, and the incidence of NRG1 fusions in non-small cell lung cancer (NSCLC) was 0.26%. It is essential to explore potential therapeutic strategies and efficacy predictors for NRG1 fusion-positive cancers. Case presentation We r...

Full description

Bibliographic Details
Main Authors: Xin Nie, Ping Zhang, Zhixin Bie, Chenhui Song, Min Zhang, Di Ma, Di Cui, Gang Cheng, Hui Li, Yan Lei, Xiaoxing Su, Wendy Wu, Lin Li
Format: Article
Language:English
Published: BMC 2023-08-01
Series:World Journal of Surgical Oncology
Subjects:
NRG1 fusion
Afatinib
Lung cancer
Next-generation sequencing (NGS)
Online Access:https://doi.org/10.1186/s12957-023-03129-z

Internet

https://doi.org/10.1186/s12957-023-03129-z

Similar Items